BYL719G
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $303,749 | 15 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $303,749 | 15 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EPIK-B2: A TWO PART, PHASE III, MULTICENTER, RANDOMIZED (1:1), DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH HER2-POSIT | Novartis Pharmaceuticals Corporation | $300,549 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,200 | 5 |
Top Doctors Receiving Payments for BYL719G
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rogers, AR | $300,549 | 5 |
| , M.D., PH.D | Medical Oncology | New York, NY | $640.00 | 2 |
| , MD | Internal Medicine | San Francisco, CA | $640.00 | 2 |
| , MD | Hematology & Oncology | Rochester, NY | $640.00 | 2 |
| , MD | Dermatology | New York, NY | $640.00 | 2 |
| , MD | Internal Medicine | Santa Monica, CA | $640.00 | 2 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $303,749
Product Information
- Type Drug
- Total Payments $303,749
- Total Doctors 5
- Transactions 15
About BYL719G
BYL719G is a drug associated with $303,749 in payments to 5 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $303,749 was paid across 15 transactions to 5 doctors.
The most common payment nature for BYL719G is "Unspecified" ($303,749, 100.0% of total).
BYL719G is associated with 2 research studies, including "EPIK-B2: A TWO PART, PHASE III, MULTICENTER, RANDOMIZED (1:1), DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH HER2-POSIT" ($300,549).